NCT04691362View on ClinicalTrials.gov

Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty

PHASE4CompletedINTERVENTIONAL

Enrollment

230

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

December 14, 2022

Study Completion Date

December 14, 2022

Conditions

Hemorrhage PostoperativeTotal Blood LossArthroplasty Complications

Interventions

DRUG

Tranexamic Acid Oral Product

Oral administration of 2 grammes tranexamic acid 2 hours before skin incision and 2 grammes oral tranexamic acid 4 hours after first administration

DRUG

Tranexamic acid injection

Intravenous administration of 1 gramme tranexamic acid 30 minutes before skin incision and 1 gramme intravenous tranexamic acid 4 hours after first administration

Trial Locations (1)

4000

CHU de Liège, Liège

All Listed Sponsors

lead

University of Liege

OTHER

NCT04691362 - Noninferiority Oral Tranexamic Acid vs Intravenous Administration in Total Hip Arthroplasty | Biotech Hunter | Biotech Hunter